PMID- 37452739
OWN - NLM
STAT- MEDLINE
DCOM- 20240209
LR  - 20240301
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 64
IP  - 10
DP  - 2023 Oct
TI  - Evolution in the frontline treatment of patients with chronic lymphocytic 
      leukemia: experience from one European center.
PG  - 1655-1661
LID - 10.1080/10428194.2023.2232489 [doi]
AB  - Treatment of chronic lymphocytic leukemia (CLL) has dramatically evolved over the 
      last decades thanks to the introduction of targeted therapies. We aimed to 
      describe retrospectively the evolution in the frontline prescription in the CLL 
      patients from our institution. As a secondary objective, the impact of frontline 
      therapy on the time-to-next-treatment (TTNT) and overall survival (OS). After a 
      median of 6.4 years (0.1-36.4) of follow-up from diagnosis, 323 of 780 CLL 
      patients (41.4%) required therapy. Alkylating agents in monotherapy 
      (chlorambucil) were the most used until 2012, and from then, chemoimmunotherapy. 
      Since 2018, targeted therapies were the most common therapeutic strategy (74.1%). 
      Patients who received targeted therapies had significantly longer TTNT compared 
      to other regimens. In the multivariable analyses, mutated IGHV genes targeted 
      therapies and chemoimmunotherapy regimens were related to longer TTNT, and sex 
      female, age younger than 65, and mutated IGHV genes were associated with better 
      OS.
FAU - Arguello-Tomas, Miguel
AU  - Arguello-Tomas M
AUID- ORCID: 0000-0002-3329-4151
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Albiol, Nil
AU  - Albiol N
AUID- ORCID: 0000-0003-2942-1362
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Hematology Department, Catalan Institute of Oncology (ICO), Hospital Universitari 
      Doctor Josep Trueta, Girona, Spain.
FAU - Jara, Paola
AU  - Jara P
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Garcia-Cadenas, Irene
AU  - Garcia-Cadenas I
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Redondo, Sara
AU  - Redondo S
AUID- ORCID: 0000-0001-8967-7410
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Esquirol, Albert
AU  - Esquirol A
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Novelli, Silvana
AU  - Novelli S
AUID- ORCID: 0000-0001-8750-0195
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Saavedra, Silvana
AU  - Saavedra S
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Martino, Rodrigo
AU  - Martino R
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Nomdedeu, Josep
AU  - Nomdedeu J
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Sierra, Jordi
AU  - Sierra J
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Mora, Alba
AU  - Mora A
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
FAU - Moreno, Carol
AU  - Moreno C
AD  - Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
AD  - Josep Carreras Leukemia Research Institute, Barcelona.
AD  - Medicine department, Universitat Autonoma de Barcelona, Barcelona.
AD  - Sant Pau Institute for Biomedical Research, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230715
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 18D0SL7309 (Chlorambucil)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/drug therapy/genetics
MH  - Retrospective Studies
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Chlorambucil
MH  - Immunotherapy
OTO - NOTNLM
OT  - CLL
OT  - frontline
OT  - prognosis
OT  - targeted therapies
EDAT- 2023/07/15 21:05
MHDA- 2024/02/09 06:42
CRDT- 2023/07/15 08:52
PHST- 2024/02/09 06:42 [medline]
PHST- 2023/07/15 21:05 [pubmed]
PHST- 2023/07/15 08:52 [entrez]
AID - 10.1080/10428194.2023.2232489 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2023 Oct;64(10):1655-1661. doi: 10.1080/10428194.2023.2232489. 
      Epub 2023 Jul 15.